Evidence map›Paper›PMID 38931468›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Oral Administration of Efavirenz Dysregulates the

Sandra Angélica Rojas-Osornio, Minerva Crespo-Ramírez, Vladimir Paredes-Cervantes, Antonio Mata-Marín, Ricardo Martínez-Lara, Miguel Pérez de la Mora, Emiliano Tesoro-Cruz

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Efavirenz-Altered Gut-Microbiota,International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra Angélica Rojas-OsornioEscuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Minerva Crespo-RamírezDivision de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Vladimir Paredes-CervantesLaboratorio Central, Hospital de Especialidades "Dr. Antonio Fraga Mouret" Centro Médico Nacional "La Raza" Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.
Antonio Mata-MarínDepartamento de Infectología, Hospital de Infectología del Centro Médico Nacional "La Raza" IMSS, Mexico City 02990, Mexico.
Ricardo Martínez-LaraUnidad de Investigación Biomédica en Inmunología e Infectología, del Hospital de Infectología del Centro Médico Nacional "La Raza" IMSS, Mexico City 02990, Mexico.
Miguel Pérez de la MoraDivision de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0003-1520-4439
Emiliano Tesoro-CruzUnidad de Investigación Biomédica en Inmunología e Infectología, del Hospital de Infectología del Centro Médico Nacional "La Raza" IMSS, Mexico City 02990, Mexico.

Funding

Fondo de Investigación en Salud (IMSS; FIS/IMSS/PROT/G14/1320) and FIS/IMSS/PROT/PRIO/18/071 FIS/IMSS/PROT/G14/1320 and FIS/IMSS/PROT/PRIO/18/071Personal Académico (DGAPA), Universidad Nacional Autónoma de México (Grant IN206820). IN206820
6 · The paper itself

Abstract

Most HIV-antiretroviral drugs have adverse effects. Efavirenz (EFV) is an example of a drug with neuropsychiatric effects, such as anxiety, depression, and suicidal thoughts, in people living with HIV (PLWH). The mechanisms by which EFV causes neuropsychiatric alterations in PLWH are complex, multifactorial, and not fully understood, although several studies in animals have reported changes in brain energy metabolism, alterations in monoamine turnover, GABA, and glutamate levels, and changes in 5-HT receptors. In this report, we studied the effects of EFV on the serotonergic system in healthy mice, specifically, whether EFV results in alterations in the levels of the tryptophan hydroxylase 2 (

Indexed as

5-HTanxietydepressionefavirenztryptophan hydroxylase 2

Identifiers

PMID38931468
PMCPMC11206422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.